Is BPC-157 legal? Regulatory status and what is documented

BPC-157 is not an approved medicine in any country. It is prohibited in sport at all times. It is marketed in the United States as an ingredient in dietary supplement capsules and tablets. All three are documented, they do not contradict each other, and none of them answers "is it legal", because each answers a different question.

Not approved means no regulator has authorised a medicine containing it. What that implies for someone who buys or holds it is a question of national law, and none of the documents behind this page addresses it. Prohibited in sport is a separate regime, binding on people competing under anti-doping rules. Being on sale is a fact FDA records, not a permission it gives.

The United States: two absences, and one residual route

FDA set out its position in a briefing document for its own advisory committee in 2026, and two absences frame everything else: there is no United States Pharmacopeia or National Formulary drug substance monograph for BPC-157 free base or its acetate form, and neither is a component of an FDA-approved drug ¹.

Those absences matter because of how compounding law is arranged. A pharmacy compounding under section 503A may use a substance covered by a pharmacopoeial monograph, or one that is a component of an approved drug; only when neither applies does the 503A Bulk Drug Substances List come into play. It is the residual route, and for BPC-157 it is the only door ¹.

FDA evaluated both forms for that list, for the treatment of ulcerative colitis, on its own initiative after both nominations were withdrawn. Weighing the physicochemical characterisation, the historical use, the lack of evidence of effectiveness and the safety information, it concluded: "we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List" ¹.

The operative word is "propose". The matter was heard by the Pharmacy Compounding Advisory Committee on 23 July 2026, and as of 2 October 2026 no vote, minutes or final determination has been published. The committee advises; its recommendations are non-binding ². A proposal about one compounding route for one indication is not a rejection and not a ban.

The Category 2 correction

BPC-157 is widely said to be on FDA's Category 2 list, for bulk substances that may present significant safety risks. In the present tense that is wrong, and the reason it is wrong matters more than the correction.

On the FDA page carrying those categories, last updated 22 April 2026, BPC-157 appears under "Bulk drug substances nominated but withdrawn". FDA describes that list as substances "previously in category 2 of the interim policies" whose nominations "were withdrawn by the nominators". So BPC-157 was in Category 2 and left it because the people who nominated it stopped asking, not because FDA reassessed the risk. The column against its name on that page is still headed "Potential significant safety risks", and the entry reads in full:

BPC-157. Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.

The last sentence is the distinction worth keeping. FDA is not recording a known harm; it is recording an inability to know. That is a weaker statement than a demonstrated risk and a stronger one than silence, and it is the position BPC-157 has been in since the nominations lapsed ³.

Sold in one channel, absent from the other

BPC-157 "is marketed in the United States as an ingredient in dietary supplement products" formulated as oral capsules and tablets, and no USP dietary supplement monograph exists for either form. In one regulated channel it is absent: FDA's outsourcing facility product reporting data, which covers facilities registered under section 503B, record no compounded products containing either form between January 2017 and June 2025 ¹. That says nothing about 503A pharmacies, which do not report products to FDA and which compounded the BPC-157 used in two of the three published human reports. FDA records the marketing and the missing standard, and says nothing about whether the marketing is lawful.

Everywhere else, through a single source

No regulator other than FDA could be reached while this page was researched, on 1 and 2 October 2026. EMA's site returned nothing and no other authority's own document could be retrieved, so each status below is FDA's account of another jurisdiction rather than that jurisdiction's own document, and should be checked against the source regulator before it is relied on.

FDA states that there is no approved product containing BPC-157-related substances in any country, and that neither form appears in the European Pharmacopoeia 11th Edition (11.8), the Japanese Pharmacopoeia 18th Edition or the International Pharmacopoeia 12th Edition. In New Zealand it records no approved products or pending applications, and that the Medicines Classification Committee at a meeting in May 2023 proposed that BPC-157 be classified as a prescription medicine ¹. That is a regulator moving toward prescription control, a direction the United States has not taken.

Sport: section S0, in and out of competition

BPC-157 is named in section S0 of WADA's Prohibited List. S0 is residual in the same way the 503A Bulks List is: it catches any pharmacological substance not addressed by another section of the list and with no current approval by any governmental regulatory health authority for human therapeutic use. BPC-157 is prohibited at all times rather than in competition only, and is classed there as a Specified Substance, which is a category the anti-doping rules use when weighing a sanction rather than a lesser form of prohibition. The list was read on 2 October 2026 ⁴.

A 2025 review states in passing that BPC-157 is not currently listed as banned ⁵. The list names it. The contrast with TB-500, in a different section under different rules, is set out in the comparison of the two.

What is documented in people

Six reports exist across two FDA systems. Five are confounded by a second product or a multi-ingredient supplement; the sixth is simply too thin to assess.

Three are in FAERS, FDA's adverse event reporting system, retrieved through 4 December 2025, all for injected BPC-157: a 55-year-old woman with nine days of injection-site redness and swelling who was also injecting compounded thymosin; a 28-year-old man using BPC-157 acetate subcutaneously who went to an emergency room with shortness of breath, nothing further recorded; and a 40-year-old woman using a BPC-157 and TB-500 product labelled "research purposes only" who developed diffuse hyperpigmentation and darkening of the gums after one week ⁶.

The third is the strongest signal in the record and it still does not resolve. She stopped the product, restarted it two weeks later, and the identical reactions reappeared. FDA's reading: "The AEs were likely due to the drug product considering that the AEs occurred upon rechallenge; however, because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs" ⁶.

Three further cases came from FDA's complaint system for foods, dietary supplements and cosmetics, retrieved through 3 December 2025, where assessment was complicated by multi-ingredient supplement use. No case report has been published: FDA identified none in the literature, and the one systematic review of this literature found no clinical safety data ¹ ⁷. The trials and uncontrolled reports in which people were actually given BPC-157 are set out in the review of its human evidence; FDA's own verdict on them was that there is "insufficient clinical safety information to characterize the safety profile" ¹.

What the animal work found

The repeat-dose toxicology ran for 28 days in rats and dogs. FDA lists as clinically relevant signals "aPTT shortening and aPTT prolongation (suggestive of altered clotting properties) in rats and dogs, respectively", and "liver-associated signals (increased serum ALT, glucose, and TG levels)" ¹. aPTT measures how long blood takes to clot: it shortened in rats and lengthened in dogs, which points to opposite risks in a person, clotting and bleeding. The two readings of this package differ, and a reader deserves both. Its authors concluded that BPC-157 was well tolerated and caused no serious toxicity in mice, rats, rabbits and dogs, and called the haematology changes in rats incidental ⁸; the systematic review reports preclinical safety studies as showing no adverse effects across several organ systems ⁷. FDA recorded those characterisations without adopting them, and listed the clotting and liver findings as clinically relevant signals instead ¹.

In the same programme BPC-157 was negative in the Ames, chromosome aberration and mouse micronucleus assays. No carcinogenicity study exists, and reproductive toxicity was tested only across gestation days 6 to 15 in rats ⁸ ¹.

The risks that are inferences

Immunogenicity, the concern FDA leaned on hardest, has never been formally studied: no study investigating the immunogenicity of BPC-157 products was identified ¹. Tumour growth is inferred from pro-angiogenic activity, which has been shown in cell and membrane assays and in a rat hind-limb model ⁹. The inference has not been tested: FDA states that it did not identify carcinogenicity studies of either form ¹. And the absences persist: no reported exposure beyond 28 days in animals or two weeks in people, and nothing covering a complete reproductive cycle ¹. Reported is the operative word, since a completed supplement study dosed 40 people for eight weeks and has posted nothing. None of these has been observed in a person, and an untested risk is not a reported harm.

One name, more than one substance

FDA found that a single common name covers multiple salts and derivatives with different active moieties, that both nomination packages contradicted themselves about which substance was being nominated, and that certificates of analysis supplied for "BPC-157" were in fact for BPC-157 acetate. It concluded that "inconsistent naming conventions ... represent a safety risk for patients as they may be dosed with a different bulk drug substance than the physician ordered" ¹.

A regulator that cannot tell from the paperwork which substance a package holds is describing a problem that arrives before any question of approval, prohibition or sale.